文献速递心胸血管麻醉神经外科与老年麻醉

艾司氯胺酮对体外循环瓣膜置换术后谵妄的影响:随机对照试验

Effect of Esketamine on Postoperative Delirium in Patients Undergoing Cardiac Valve Replacement with Cardiopulmonary Bypass: A Randomized Controlled Trial.
PubMed 文献 · Anesth Analg · 2024-03-06

该随机三盲对照试验纳入116例ASA Ⅱ~Ⅲ级、NYHA Ⅱ~Ⅲ级行体外循环心脏瓣膜手术的成人患者,麻醉诱导前静脉给予艾司氯胺酮0.25 mg/kg或生理盐水。

要点

  • 麻醉诱导前单次静脉注射艾司氯胺酮0.25 mg/kg可降低体外循环瓣膜术后谵妄发生率。
  • 艾司氯胺酮还减少谵妄多次发作和高活动型亚型,但认知功能评估结果未在摘要中报告。

核心结论

  • 麻醉诱导前单次静脉注射艾司氯胺酮0.25 mg/kg可降低相对年轻、ASA Ⅱ或Ⅲ级患者体外循环心脏瓣膜术后谵妄的发生率。

研究设计与样本

  • 随机、三盲、对照试验,纳入116例ASA Ⅱ或Ⅲ级、NYHA Ⅱ或Ⅲ级行体外循环心脏瓣膜手术的成人患者。
  • 艾司氯胺酮0.25 mg/kg或生理盐水在麻醉诱导前静脉给药,最终112例纳入分析(艾司氯胺酮组56例,安慰剂组56例)。

主要发现

  • 多次谵妄发作在艾司氯胺酮组为23.2%(13/56),安慰剂组为42.9%(24/56),RR 0.54,95%CI 0.28-0.92。
  • 高活动型亚型在艾司氯胺酮组为23.2%(13/56),安慰剂组为39.3%(22/56)。

临床怎么用

  • 对于ASA Ⅱ或Ⅲ级、NYHA Ⅱ或Ⅲ级行体外循环心脏瓣膜手术的成人患者,可考虑麻醉诱导前单次静脉注射艾司氯胺酮0.25 mg/kg以降低术后谵妄风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to investigate the effects of esketamine on the risk of postoperative delirium (POD) in adults undergoing on-pump cardiac valve surgery. METHODS: In this randomized, triple-blind, controlled trial, 116 adult patients with an American Society of Anesthesiologists (ASA) grade Ⅱ or Ⅲ and a New York Heart Association (NYHA) grade Ⅱ or Ⅲ who underwent cardiac valve surgery with cardiopulmonary bypass were included. Esketamine (0.25 mg/kg) or normal saline was administered intravenously before anesthesia induction. The primary outcome was POD, defined as a positive delirium assessment according to the 3-minute confusion assessment method (CAM) or the confusion assessment method for the intensive care unit (CAM-ICU) on a twice-daily basis for 7 days after surgery. Delirium duration and the delirium subtype were also recorded. The cognitive status of patients was measured according to the Mini-Mental State Examination at baseline, discharge, 30 days postoperatively and 3 months postoperatively. RESULTS: A total of 112 patients (mean age, 52 years; 53.6% female) were enrolled; 56 were assigned to receive esketamine, and 56 were assigned to receive placebo. POD occurred in 13 (23.2%) patients in the esketamine group and in 25 (44.6%) patients in the placebo group (relative risk [RR], 0.52, 95% confidence interval [CI], 0.28-0.91; P = .018). Thirteen patients (23.2%) in the esketamine group and 24 (42.9%) patients in the placebo group had multiple episodes of delirium (RR, 0.54, 95% CI, 0.28-0.92), and 13 (23.2%) vs 22 (39.3%) patients exhibited the hyperactive subtype. CONCLUSIONS: A single dose of esketamine (0.25 mg/kg) injected intravenously before anesthesia induction reduced the incidence of delirium in relatively young patients with ASA grade Ⅱ or Ⅲ who underwent on-pump cardiac surgery.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Xiong X, Shao Y, Chen D, et al. Effect of Esketamine on Postoperative Delirium in Patients Undergoing Cardiac Valve Replacement with Cardiopulmonary Bypass: A Randomized Controlled Trial. Anesth Analg. 2024. PMID: 38446699. doi:10.1213/ANE.0000000000006925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。